Search research articles
Contact Us
Filters
Showing results (511-520 of 525) with videos related to
Page
of 53
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
ESMO Open
|
August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Robin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
Steven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 25, 2019
International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis
M A Kempeneers, Y Issa, U Ahmed Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
The Lancet. Oncology
|
June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 5, 2018
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
Page
of 53
Search research articles
Search
Showing results (511-520 of 525) with videos related to
Sort By:
Page
of 53
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 12, 2024
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial
D Baron, T Pace Loscos, R Schiappa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D Arnold, C S Fuchs, J Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S Finn, Masafumi Ikeda, Andrew X Zhu, et al.
ESMO Open
|
August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
Robin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
Steven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
December 25, 2019
International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis
M A Kempeneers, Y Issa, U Ahmed Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
Richard S Finn, Masatoshi Kudo, Ann-Lii Cheng, et al.
The Lancet. Oncology
|
June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 5, 2018
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.
Page
of 53